Farallon Capital Management’s Kailera Therapeutics KLRA Stock Holding History

Farallon Capital Management’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.2M	Buy	+1,100,000	New	+$24.2M	0.11%	50

Other funds holding KLRA

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Farallon Capital Management's KLRA Position: Q2 2026 in Review

Farallon Capital Management opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 1,100,000 shares worth $24.2M. The stake represents 0.11% of the portfolio and ranks #50 among its holdings.

99 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Farallon Capital Management held 1,100,000 shares of Kailera Therapeutics worth $24.2M as of Q2 2026.
Kailera Therapeutics was a new Farallon Capital Management position in Q2 2026.
Kailera Therapeutics made up 0.11% of Farallon Capital Management's portfolio in Q2 2026, its #50 holding.
99 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.